Systemic antifungal drugs

Revista Iberoamericana de Micologia

Volumn 17, Issue SUPPL., 2000, Pages 168-174

  Graybill, J R ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Antifungal; Echinocandin; Liposome; Polyene; Triazole

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; ECHINOCANDIN B; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; DRUG USE; HUMAN; MYCOSIS; TREATMENT INDICATION;

EID: 0033814496     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (109)

1. Amphotericin B: 30 years of clinical experience
2. Amphotericin B: A commentary on its role as an antifungal agent and as a comparative agent in clinical trials
3. Pharmacology and toxicity of high-dose ketoconazole
4. Terbinafine treatment of cutaneous sporotrichosis : Initial results from a phase II/III trial
5. Coccidioidomycosis during human immunodeficiency virus infection
6. Disseminated histoplasmosis in the acquired immunodeficiency syndrome: Clinical findings, diagnosis and treatment and review of the literature
7. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome
8. Pulmonary aspergillosis in the acquired immunodeficiency syndrome
9. Oropharyngeal and esophageal candidiasis in immunocompromised patients: Treatment issues
10. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
11. Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses
12. Risk factors for hospital-acquired candidemia
13. Candidemia in a tertiary care hospital: Epidemiology, risk factors, and predictors of mortality
14. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: Frequency, characteristics, and evaluation of factors influencing outcome
15. The changing face of nosocomial candidemia: Epidemiology, resistance, and drug therapy
16. Epidemiology of invasive fungal infections in bone marrow transplantation
17. Editorial response: Evolving risk factors for invasive fungal infections - All neutropenic patients are not the same
18. Nosocomial fungal infections
19. Emerging fungal pathogens
20. New spectrum of fungal infections in patients with cancer
21. Emerging fungal pathogens in immunocompromised patients: Classification, diagnosis, and management
22. Zygomycosis
23. Invasive aspergillosis
24. Fatal disseminated infection with Aspergittus terreus in immunocompromised hosts
25. Trichosporon beigelii fungemia and metastasic pneumonia in a trauma patient
26. Use of the Pastorex aspergillus antigen latex agglutination test for the diagnosis of invasive aspergillosis
27. Clinical evaluation and reproducibility of the Pastorex Aspergillus antigen latex agglutination test for diagnosing invasive aspergillosis
28. Amphotericin B: Current understanding of mechanisms of action
29. Erythropoietin concentration in amphotericin B induced anemia
30. Effect of amphotericin B on growth and membrane permeability in Dictyostelium discoideum
31. Risk factors of ventricular fibrillation during rapid amphotericin B infusion
32. Amphotericin B nephrotoxicity in humans decreased by salt repletion
33. The effect of amphotericin B on the K-channel activity of MDCK cells
34. The polyene antibiotic amphotericin B inhibits the Na+/K+ pump of human erythrocytes
35. Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes
36. Resistance to amphotericin B associated with defective sterol Delta8→7 isomerase in a Cryptococcus neoformans strain from an AIDS patient
37. Candida lusitaniae: Frequency of recovery, colonization, infection, and amphotericin B resistance
38. Development of resistance to amphotericin B in Candida lusitaniae infecring a human
39. Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii
40. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B
41. Fatal native valve endocarditis due to Scedosporium apiospermum (Pseudallescheria boydii) following trauma
42. Risk of ventricular dysrhythmias during 1-hour infusions of amphotericin B in patients with preserved renal function
43. Coccidioidal meningitis
44. Pharmacokinetics of intrathecally administered amphotericin B
45. Fluconazole therapy for coccidioidal meningitis
46. Pharmacokinetics of liposomal nystatin in patients with human immunodeficiency virus infection
47. Commentary: Liposomes: The future ahead
48. Clinical use of liposomal and lipid-complexed amphotericin B
49. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs amphotericin B in the empirical treatment of fever and neutropenic
50. Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and disseminated candidiasis
51. Lipid formulations for amphotericin B: Does the emperor need new clothes?
52. Highdose liposomal amphotericin B in patients infected with aspergillosis and other filamentous fungi
53. Randomized double-blind trial of AmBisome (liposomal amphotericin B)and amphotericin B in acute cryptococal meningitis in AIDS patients
54. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
55. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
56. Failure of a lipid amphotericin B preparation to eradicate candiduria: Preliminary findings based on three cases
57. An EORTC international multicenter randomized trial (EORTC Number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
58. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients
59. Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits
60. A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia
61. Efficacy and tolerance of an amphotericin B lipid (intralipid) emulsion in the treatment of candidemia in neutropenic patients
62. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis
63. Evolving role of flucytosine in immunocompromised patients: New insights into safety, pharmacokinetics, and antifungal therapy
64. Evidence for convrsion of 5-fluorocytosine in 5-fluorouracil in humans: Possible factor in 5-fluorocytosine clinical toxicity
65. International conference for the development of a consensus on the management and prevention of severe candidal infections
66. Oral azole drugs as systemic antifungal therapy
67. Biochemical targets for antifungal azole derivatives: Hypothesis on the mode of action
68. Clotrimazole
69. Effects of ketoconazole on cholesterol precursors and low density lipoprotein kinetics in hypercholesterolemia
70. Hepatic injury associated with ketoconazole therapy
71. Effect of high dose ketoconazole on adrenal and testicular function
72. Ketoconazole blocks testosterone synthesis
73. Interaction of triazolam and ketoconazole
74. The modern revolution in antifungal chemotherapy
75. Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections
76. Treatment of systemic sporotrichosis with ketoconazole
77. Fluconazole - An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients
78. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs
79. The efficacy and tolerability of UK109,496 (Voriconazole) in the treatment of invasive aspergillosis
80. Activity of a new triazole, SCH56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae
81. SCH59884, a water-soluble prodrug of SCH56592 for intravenous formulations
82. SCH59884, the intravenous prodrug of the antifungal SCH56592
83. Pharmacokinetics of SCH59884, an IV prodrug for the oral antifungal SCH56592 in animals and its conversion to SCH58592 by human tissues
84. Itraconazole treatment of phaeohyphomycosis
85. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole
86. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome
87. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome
88. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: Randomized, placebo-controlled, double-blind study
89. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis
90. Itraconazole treatment of coccidiodomycosis
91. Coccidioidomycosis: A regional disease of national importance - Rethinking approaches for control
92. SCH56592 treatment of murine invasive aspergillosis
93. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain
94. Comparison of the in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
95. An in vitro head-to-head comparison of Schering 56592, amphotericin B, fluconazole, and itraconazole against a spectrum of filamentous fungi
96. The effect of co-administration of a cola beverage on the bioavailability of itraconazole in AIDS patients
97. The pharmacokinetic rationale behind intravenous itraconazole
98. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole colution in patients in intensive care units
99. Efficacy, safety, and pharmacokinetics of intravenous (IV) followed by oral itraconazole (ITR) in patietns (pts) with invasive pulmonary aspergillosis (IPA)
100. High dose itraconazole in the treatment of severe mycoses
101. Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole
102. Compounds active against cell walls of medically important fungi
103. In vitro evaluation of the pneumocandin antifungal agent L-733580, a new water-soluble hybrid of L-705589 and L-731373
104. Antifungal agents: Novel therapeutic compounds against emerging pathogens
105. In vitro studies with L-743,872, a water soluble pneumocandin: A comparative study
106. Antifungal agents: Chemotherapeutic targets and immunologic strategies
107. In vitro synergy of pneumocandin L-743872 with fluconazole and amphotericin B against Cryptococcus neoformans
108. A multicenter study to determine the minimal effective dose of FK463 for the treatment of esophagela candidiasis in HIV positive patients
109. A randomized double-blind multicenter trial of (MK-0991), an echinocandin antifungal agent, vs amphotericin B for ttreatment of oropharyngeal (OPC) and esophageal (EC] candidiasis in adults